Clinical Trial

Benefits of Nicotinamide Riboside Upon Cognition and Sleep

Recruiting
View on ClinicalTrials.gov →
Summary
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-10; most recent amendment 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2023-09-19
Trial Details
NCT Number NCT05500170
Lead Sponsor State University of New York at Buffalo
Conditions Cognitive Impairment, Sleep Quality
Enrollment 50 participants
Start Date 2023-04-04
Primary Completion 2027-08-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-22